Clinical observation of Xinmaitong capsule combined with atorvastatin calcium tablet in the treatment of hypertension with elevated plasma lipoprotein phospholipase A2

Objective To analyze the efficacy and safety of Xinmaitong capsule combined with Atorvastatin calcium tablets in the treatment of hypertension with elevated plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), and to provide a new method for the treatment of hypertension with elevated plasma Lp-PLA2. Methods Total 126 cases of hypertension with elevated plasma Lp-PLA2 in our hospital between January 2017 and June 2018 were enrolled into this study and randomly divided into experimental group and control group, with 63 cases in each group. In the experimental group, the patients received Xinmaitong capsules (3 pills every time, tid.) and Atorvastatin calcium tablets (10 mg/time, qd.); in the control group, the patients were given Atorvastatin calcium tablets (10 mg/time, qd.). After 8 weeks of treatment, the values of Lp-PLA2, low density lipoprotein cholesterol (LDL-C) and arteriosclerosis in the two groups were determined, and adverse drug reactions were recorded. SPSS 20.0 statistical software was used to analyze the data. Results The levels of Lp-PLA2, LDL-C and atherosclerosis in the experimental group and the control group decreased at week 8 after treatment compared with those before the treatment, especially in the experimental group, the difference was statistically significant (all P<0.05), while the rates of adverse drug reactions in both groups were not statistically significant (P>0.05). Conclusion The Lp-PLA2, LDL-C and atherosclerosis index of patients with hypertension can be significantly improved by Xinmai tong capsule combined with Atorvastatin calcium tablets, without obvious increase in the incidence of adverse reactions.